Browse Antimitotic agents topic

Licensing agreements subtopic

Articles 1-18 out of 18 article(s) Title Author Type Date Words United States: Ipsen and Spirogen enter into new agreement for development of SJG-136. Oct 9, 2009 291 Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation of the Ipsen's Proprietary CDC-251 Inhibitor (IRC-083864 or Debio 0931) an Anti-Cancer Agent. Sep 7, 2009 1126 SymBio Pharmaceuticals Limited and Eisai Co., Ltd. Conclude License Agreement for Bendamustine Hydrochloride (SyB L-0501) in Korea and Singapore. May 18, 2009 649 Antyra Enters into Licensing Agreement for Anticancer Agents from Novo Nordisk A/S. Nov 12, 2008 629 GPC Biotech Reports that Celgene to Terminate Co-Development and License Agreement for Satraplatin. Aug 6, 2008 392 BioInvent and ThromboGenics Announce a Strategic Alliance with Roche for TB-403, A Novel Anti-Cancer Antibody. Jun 18, 2008 1395 Morphotek(R) Signs Exclusive Licensing Agreement for Anti-Cancer Antibody. Mar 6, 2008 492 Caprion Pharmaceuticals Enters Into Oncology Target Licensing Agreement with Centocor Research and Development, Inc. Oct 11, 2006 269 MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson & Johnson Company, for Dacogen(TM) (decitabine) for Injection; Ex-North America Development & Commercialization Agreement. Jul 6, 2006 919 Florida Atlantic licenses cancer therapy to CHS Resources LLC Therapy. Jun 1, 2006 1346 Affitech Renews Exclusive Worldwide Phage Display License From DKFZ; 'Breitling' Patents Hold Key Position in Human Antibody Discovery Field. Apr 9, 2006 332 Immusol Announces an Exclusive Worldwide License Agreement with Baylor College of Medicine for a Novel Cancer Therapy. Feb 1, 2006 514 Caprion Pharmaceuticals Enters Into Oncology Target Licensing Agreement with ImClone Systems. Jan 10, 2006 319 Sonus Pharmaceuticals and Schering AG Announce Global Licensing Agreement for Anti-cancer Product TOCOSOL(R) Paclitaxel. Oct 18, 2005 1352 EntreMed and Celgene enter into licensing agreement for the development of tubulin inhibitor cancer drugs. Mar 1, 2005 575 Prolexys licenses anti-cancer compounds. Feb 1, 2005 435 Protein Design Labs licenses development rights to leukemia antibody. Mar 1, 2003 530 FDA approves Novartis' Gleevec for first line treatment of chronic myeloid leukemia. Brief Article Dec 27, 2002 171